Biotech Values

[DewDiligence]

PFE should forget about trying to replace the sales that will be lost to patent expirations because this can’t be done without incurring even greater problems.

Instead, PFE should continue to downsize and should aggressively leverage the balance sheet to the point where ROE becomes impressive. Doing this would leave a very different company, but it’s the best chance to increase shareholder value, IMO.